Mydecine Innovations Group Announces Major Patent Progress for Novel Psilocin Analog

LOS ANGELES-  Mydecine Innovations Group Inc, a biotechnology company in mental health and addiction treatment, has recently announced a significant breakthrough. The United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the company’s MYCO-005 compound, titled “Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same Unique Compound (US20230348380A1)”. This Composition of Matter patent reflects Mydecine’s dedication to innovating mental health therapeutics.

MYCO-005, a unique compound developed by Mydecine, is designed to therapeutically mimic psilocin, a naturally occurring psychedelic compound. This new analog aims to reduce the undesirable side effects associated with the long-term use of psilocybin and similar serotonin agonists like LSD and DMT. Notably, MYCO-005 addresses valvular fibrosis concerns, a significant issue acknowledged by clinicians and FDA regulators.

The innovative compound demonstrates selective binding to 5-HT2A receptors while avoiding the 5-HT2B receptors, which are often associated with cardiovascular risks. This feature makes MYCO-005 a potentially safer option for both macro and microdosing applications.

In 2020, Mydecine filed a provisional patent application covering multiple families of psilocin analogs. MYCO-005 has emerged as a leading second-generation compound, addressing stability and receptor binding concerns of earlier compounds. It introduces a novel analog that is potentially safer for the heart, especially for microdose treatments.

Microdosing, which is increasingly recognized for its potential in treating ADHD, depression, and anxiety, is often limited by the cardiovascular risks linked to psilocybin. Rob Roscow, the Chief Scientific Officer at Mydecine, emphasized the risks associated with the 5-HT2B receptor and heart valve tissue fibrosis. He stated, “MYCO-005’s research shows strong binding to the classic psychedelic 5-HT2A receptor while avoiding the 5-HT2B receptor, suggesting an enhanced safety profile for microdosing.”

With this advancement, MYCO-005 positions itself as a safer alternative for individuals dealing with anxiety or depression disorders, marking a significant step forward in mental health treatment.

Mydecine Innovations Group continues to be at the forefront of biotechnological advancements, committed to developing safer and more effective solutions for mental health and addiction disorders.

The Directors of Mydecine have taken responsibility for this announcement, which contains inside information as per Article 7 of the Market Abuse Regulation (EU) 596/2014, integrated into UK law under the European Union (Withdrawal) Act 2018. The disclosure is in line with the Company’s obligations under Article 17 of the same regulation.